logo-loader
viewPharmaxis Ltd

Pharmaxis begins dosing patients in phase Ib study

This drug is targeting the treatment of cancers including myelofibrosis and pancreatic cancer.

Pharmaxis Ltd - Pharmaxis begins dosing patients in phase Ib study
Pharmaxis was recently ranked 38 in the top 100 most innovative pharma companies in APAC

Pharmaxis Ltd (ASX:PXS) has commenced dosing subjects in phase Ib of its study of an oral anti‐fibrotic Lysyl Oxidase (LOX) inhibitor targeting the treatment of cancers.

Phase Ib follows the success of phase Ia which commenced in February 2019 and consisted of 40 healthy subjects divided into five groups, each taking a dose or a placebo.

The drug was well tolerated and no safety signals were identified in phase Ia.

Phase Ib involves 16 subjects in two groups with each group receiving a different dose or placebo for 14 days.

The clinical trial is due to report in the March quarter of 2020.

Aim to progress to clinical proof of concept studies

Pharmaxis’ CEO Gary Phillips said: “The second part of this study was originally due to report mid‐year but we delayed it while we completed 3‐month toxicity testing to further de‐risk the drug.

“This means that with successful completion of this phase 1 study we will have all the data required to support the commencement of clinical proof of concept studies in either myelofibrosis or pancreatic cancer. 

“Pharmaxis plans to discuss this program with the FDA in coming months prior to filing an IND that supports entering phase 2 studies in 2H 2020.”

Proprietary technology to be used

Phillips added: “Our expertise in the biology and chemistry of lysyl oxidase inhibitors, including the LOX and LOXL2 programs has been featured in a number of international conferences and publications in recent months.

“We have developed proprietary technology to measure LOX and its related family of enzymes in both animal models and human plasma that enables us to clearly understand the role these enzymes have in fibrotic disease.

“This will significantly aid patient selection and proof‐of‐mechanism in the upcoming phase 2 trials.”

Pharmaxis ranked in top 100

Pharmaxis was recently included in a report ranking it among the top 100 most innovative pharma companies in the Asia Pacific (APAC) region.

The report was prepared by Cortellis and is entitled ‘Pharmaceutical innovation in the APAC region’.

It studied a cohort of 929 companies including multi-nationals across 14 countries/regions that have or are developing innovative pharmaceutical products.

Notably, 14 Australian companies featured in the top-100 and Pharmaxis was the second-highest ranked.

Quick facts: Pharmaxis Ltd

Price: 0.08 AUD

ASX:PXS
Market: ASX
Market Cap: $31.66 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read